metaEvidence - overview


			deaths (OS)
mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population
versus interferon alpha
	Ipilimumab (10 mg/kg) vs. interferon alpha	1	0.88 [0.69; 1.12], 1 RCT, I2=0% inconclusive result
	ipilimumab alone vs. interferon alpha	1	0.83 [0.70; 0.98], 2 RCTs, I2=0% conclusive low degree of certainty
versus Ipilimumab (10 mg/kg)
	nivolumab alone vs. Ipilimumab (10 mg/kg)	1	0.87 [0.66; 1.14], 1 RCT, I2=0% inconclusive result
versus nivolumab alone
	nivolumab plus ipilimumab vs. nivolumab alone	1	-
versus placebo
	Ipilimumab (10 mg/kg) vs. placebo	1	0.72 [0.58; 0.89], 1 RCT, I2=0% conclusive unassessable degree of certainty
	nivolumab alone vs. placebo	1	-
	nivolumab plus ipilimumab vs. placebo	1	-
	pembrolizumab alone vs. placebo	1	-
mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive
versus placebo
	pembrolizumab alone vs. placebo	1	-